论文部分内容阅读
320例肾母细胞瘤获远期随访235例。依治疗时间及治疗方法不同分无化疗组、化疗组、规律化疗组。规律化疗组预后好的组织结构(FH)81例,四年无瘤生存Ⅰ期95.8%,Ⅱ期83.3%,Ⅲ期63.6%,Ⅳ期40.0%;预后差的组织结构(UH)12例,四年无瘤生存Ⅰ期50.0%,Ⅲ期16.7%。在病理组织分型和一定的临床分期情况下,合理的综合治疗特别是规律性化疗是影响肾母细胞瘤预后的重要因素。
320 cases of nephroblastoma were followed up for 235 cases. According to the treatment time and different treatment points chemotherapy-free group, chemotherapy group, regular chemotherapy group. In the regular chemotherapy group, there were 81 cases with good prognosis of histopathology (FH). The four-year disease free survival was 95.8% in stage Ⅰ, 83.3% in stage Ⅱ, 63.6% in stage Ⅲ and 40.0% in stage Ⅳ. The poor prognosis Tissue structure (UH) in 12 cases, four-year disease-free survival of stage Ⅰ 50.0%, Ⅲ stage 16.7%. In the pathological tissue typing and a certain clinical staging, reasonable comprehensive treatment, especially regular chemotherapy is an important factor affecting the prognosis of nephroblastoma.